Lazanda
Product Images NDC 71500-140

Product Visual Gallery

This gallery contains 18 technical images submitted to the FDA as part of the official labeling for Lazanda (NDC 71500-140). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by West Therapeutic Development Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Clin Pharm Fig 1 (Clinical Pharmacology Figure 1)

A line graph showing mean plasma fentanyl concentrations (pg/mL) over time (hours) for LAZANDA nasal spray at four doses (100, 200, 400, and 800 mcg) compared to OTFC 200 mcg. The y-axis represents fentanyl plasma levels with error bars for standard deviation, and the x-axis shows time up to 4 hours.*

FDA Label Image

Clin Stud Fig 2 (Clinical Studies Figure 2)

A line graph comparing the PID (SE) over time (minutes) between Lazanda and a placebo. The graph shows two curves with Lazanda data points consistently higher than placebo from 5 to 60 minutes, indicating a difference in measured response between the two groups.*

FDA Label Image

Lazanda Titration Process (Lazanda Titration Process)

Flowchart illustrating the Lazanda titration process. It starts at 100 mcg (one spray in one nostril), followed by administration instructions. The process asks if pain relief is adequate after 30 minutes, with paths to continue the same dose or increase to a higher dose for the next pain episode. The diagram concludes with identifying the successful dose.*

FDA Label Image

Principal Display Panel (100 mcg carton)

LAZANDA 100 mcg per spray packaging label for fentanyl nasal spray by West Therapeutic Development LLC. The label indicates the product is for nasal administration only and includes dispensing instructions, warnings, and storage information. The box design includes product and company logos, dosage strength, and a section for pharmacy labeling.*

FDA Label Image

Principal Display Panel (300 mcg)

LAZANDA fentanyl nasal spray packaging label showing 300 mcg per spray strength. The label includes dosage instructions, warnings, and distribution information. It also references the enclosed Medication Guide and indicates the product is for nasal administration only. The labeler is West Therapeutic Development LLC.*

FDA Label Image

Principal Display Panel (400 mcg carton)

LAZANDA 400 mcg per spray fentanyl nasal spray carton label. The package specifies nasal administration only and includes instructions to dispense the enclosed Medication Guide. It lists the labeler as West Therapeutic Development LLC and includes warnings about opioid therapy tolerance and handling instructions. The label also notes the restricted distribution program for LAZANDA and provides contact information for access.*

FDA Label Image

Principal Display Panel (100 mcg)

Label for LAZANDA fentanyl nasal spray, showing a strength of 100 mcg per spray. The label includes the brand name Lazanda, a barcode, and a note to return the container to child-resistant storage after use. It is distributed by West Therapeutic Development LLC. Additional printing and approval information is shown below the main label.*

FDA Label Image

Principal Display Panel (300 mcg)

Label for LAZANDA fentanyl nasal spray, showing a dosage strength of 300 mcg per spray. The label includes a barcode and text indicating it is distributed by West Therapeutic Development LLC. There is a lot and expiration date section and a note to return the container to child-resistant storage after use.*

FDA Label Image

Principal Display Panel (400 mcg)

Label for LAZANDA fentanyl nasal spray showing strength of 400 mcg per spray. The label instructs to return to a child-resistant container after use and displays the labeler as West Therapeutic Development LLC. Includes a barcode, Rx only symbol, and spaces for lot and expiration dates.*

FDA Label Image

Lazanda Structure (Lazanda Structure)

Chemical structure diagram of the active ingredient(s) in LAZANDA, showing molecular arrangements including nitrogen-containing rings and carboxylic acid groups.*

FDA Label Image

Med Guide Fig 1 (Med Guide Fig 1)

This medication guide covers LAZANDA (fentanyl) nasal spray. It provides important safety information about opioid tolerance, overdose risks, and instructions for use. The guide details conditions for use, warnings about interactions, and requirements for enrollment in a risk management program. It also lists contraindications and advice on when not to take LAZANDA.*

FDA Label Image

Med Guide Fig 2 (Med Guide Fig 2)

Drug facts and usage instructions for LAZANDA, including warnings, precautions, dosing instructions, disposal guidelines, possible side effects, and emergency contact information. The text advises consultation with a healthcare provider regarding history, pregnancy, and medication use, details spray administration methods, and lists symptoms requiring immediate medical attention.*

FDA Label Image

Med Guide Fig 7 (Med Guide Fig 7)

This text panel provides instructions for patients who lose the Lazanda pouch, including how to order a replacement. It advises opening a new bottle and consulting the Medication Guide for further use instructions. The panel states that the guide is approved by the FDA and includes revision and copyright information from West Therapeutic Development LLC dated March 2021.*

FDA Label Image

Medguide Page 3 (Medguide 3)

This panel includes ingredients and detailed instructions for using Lazanda, containing fentanyl citrate as the active ingredient. It explains the contents of a Lazanda pack, including a cardboard box, child-resistant container, disposal pouch, and bottle. The image also shows labeled figures of the child-resistant container, disposal pouch, and bottle cap along with instructions for preparing and priming the Lazanda bottle for use.*

FDA Label Image

Medguide Page 4 (Medguide 4)

Instructional images showing steps to prepare and use a Lazanda spray bottle. Includes removing the protective cap, placing the bottle into a pouch, observing red and green bars in the counting window to indicate readiness, removing the bottle from the pouch, and storage instructions. Additional images depict counting window details with red and green bars and a numerical display for usage status.*

FDA Label Image

Medguide Page 5 (Medguide 5)

Illustrations and instructions for administering LAZANDA nasal spray, including holding the bottle (Figure N), inserting the tip into the nostril and tilting the bottle (Figure O), closing the other nostril (Figure P), and replacing the protective cap after use (Figure Q). The text details step-by-step spray usage and disposal guidelines.*

FDA Label Image

Medguide Page 6 (Medguide 6)

Instructional text panel for Lazanda spray bottle disposal, detailing step-by-step procedures to empty remaining medicine into a pouch, use the counting window numbered '8', and properly seal and dispose of the bottle and pouch. Includes four supporting photographs labeled Figure R, S, T, and U showing grip pressing, counting window, sealing the pouch, and folding the flap.*

FDA Label Image

Principal Display Panel (pouch)

LAZANDA disposable pouch label by West Therapeutic Development LLC. The label includes usage instructions indicating it is for use only with LAZANDA, states it contains no active drug ingredient, and advises users to refer to the Medication Guide for proper use. The label shows contact information for the manufacturer and includes barcode and lot number details.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.